1nzg
From Proteopedia
(Difference between revisions)
| (One intermediate revision not shown.) | |||
| Line 4: | Line 4: | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[1nzg]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1NZG OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1NZG FirstGlance]. <br> | <table><tr><td colspan='2'>[[1nzg]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1NZG OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1NZG FirstGlance]. <br> | ||
| - | </td></tr><tr id=' | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.6Å</td></tr> |
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=3ME:2-O-{2-[2-(DIMETHYLAMINO)ETHOXY]ETHYL}-5-METHYLURIDINE+5-(DIHYDROGEN+PHOSPHATE)'>3ME</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1nzg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1nzg OCA], [https://pdbe.org/1nzg PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=1nzg RCSB], [https://www.ebi.ac.uk/pdbsum/1nzg PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1nzg ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1nzg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1nzg OCA], [https://pdbe.org/1nzg PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=1nzg RCSB], [https://www.ebi.ac.uk/pdbsum/1nzg PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1nzg ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| - | <div style="background-color:#fffaf0;"> | ||
| - | == Publication Abstract from PubMed == | ||
| - | [structure: see text] Oligonucleotides with a novel, 2'-O-[2-[2-(N,N-dimethylamino)ethoxy]ethyl] (2'-O-DMAEOE) modification have been synthesized. This modification, a cationic analogue of the 2'-O-(2-methoxyethyl) (2'-O-MOE) modification, exhibits high binding affinity to target RNA (but not to DNA) and exceptional resistance to nuclease degradation. Analysis of the crystal structure of a self-complementary oligonucleotide containing a single 2'-O-DMAEOE modification explains the importance of charge factors and gauche effects on the observed antisense properties. 2'-O-DMAEOE modified oligonucleotides are ideal candidates for antisense drugs. | ||
| - | |||
| - | 2'-O-[2-[2-(N,N-dimethylamino)ethoxy]ethyl] modified oligonucleotides: symbiosis of charge interaction factors and stereoelectronic effects.,Prhavc M, Prakash TP, Minasov G, Cook PD, Egli M, Manoharan M Org Lett. 2003 Jun 12;5(12):2017-20. PMID:12790517<ref>PMID:12790517</ref> | ||
| - | |||
| - | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| - | </div> | ||
| - | <div class="pdbe-citations 1nzg" style="background-color:#fffaf0;"></div> | ||
| - | == References == | ||
| - | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| - | [[Category: Egli | + | [[Category: Egli M]] |
| - | [[Category: Manoharan | + | [[Category: Manoharan M]] |
| - | [[Category: Minasov | + | [[Category: Minasov G]] |
| - | [[Category: Prakash | + | [[Category: Prakash TP]] |
| - | [[Category: Prhavc | + | [[Category: Prhavc M]] |
| - | + | ||
| - | + | ||
| - | + | ||
Current revision
Crystal structure of A-DNA decamer GCGTA(3ME)ACGC, with a modified 5-methyluridine
| |||||||||||
